MOUNTAIN VIEW, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Omnicell, Inc. , a leading provider of system solutions to acute healthcare facilities, today announced results for its third quarter ended September 30, 2007.
GAAP results: Revenues for the third quarter of 2007 totaled $55.2 million, up $3.3 million or 6.4% from second quarter 2007 revenue of $51.8 million, and up $13.9 million or 33.8% from the third quarter of 2006.
Third quarter 2007 net income as reported in accordance with U.S. generally accepted accounting principles (GAAP) was $6.9 million, or $0.19 per fully diluted share. Third quarter net income compares to net income of $18.1 million, or $0.55 per fully diluted share in the second quarter of 2007, including $12.8 million of income tax benefits related to the partial reversal of our tax valuation allowance in the second quarter of 2007; and $3.1 million, or $0.11 per fully diluted share in the third quarter of 2006. For the first nine months of 2007, net income was $29.0 million, or $0.88 per fully diluted share, of which $0.39 is represented by the same $12.8 million of income tax benefits related to the partial reversal of our tax valuation allowance in the second quarter of 2007. This compares to net income of $6.3 million or $0.22 per fully diluted share for the first nine months of 2006. Product backlog grew to $140.6 million, up $9.1 million from the quarter ended June 30, 2007.
Non-GAAP results: Excluding the impact on our results of recording $2.8 million in share-based compensation expenses related to SFAS No. 123R, non- GAAP net income was $9.8 million for the quarter ended September 30, 2007, or $0.27 per fully diluted share. This compares to non-GAAP income of $7.9 million or $0.24 per fully diluted share for the second quarter of 2007 and third quarter 2006 non-GAAP net income of $5.2 million or $0.18 per fully diluted share. Excluding $8.0 million in share-based compensation expenses related to SFAS No.123R and $12.8 million in income tax benefits related to a partial reversal of our tax valuation allowance, non-GAAP net income was $24.3 million for the nine months ended September 30, 2007, or $0.74 per fully diluted share. This compares to non-GAAP net income of $12.4 million or $0.43 per fully diluted share for the first nine months of 2006.
“Omnicell delivered another quarter of solid financial performance as demonstrated by our earnings, with new customers expressing their confidence in our solutions,” said Randall A. Lipps, Omnicell president and chief executive officer. “We remain focused on delivering the best customer experience in healthcare and help our customers to continually improve patient safety.”
Omnicell Conference Call Information
Omnicell will hold a conference call today at 2:30 p.m. PDT to discuss third quarter financial results. The number is 1-888-803-5209 within the U.S. or 1-706-679-1978 for all other locations. Internet users can access the conference call at www.omnicell.com. A replay of the call will be available today at approximately 5:30 p.m. PDT and will be available for one week or until October 25. The replay access numbers are 1-800-642-1687 within the U.S. and 1-706-645-9291 for all other locations, passcode 19980216#.
About Omnicell
Omnicell, Inc. is a leading provider of system solutions to acute healthcare facilities. Since 1992, Omnicell has worked to enhance patient safety and allow clinicians to spend more time with their patients.
Omnicell’s medication-use product line includes solutions for the central pharmacy, nursing unit, operating room, and patient bedside. Solutions range from large central pharmacy “smart inventory” carousels to small handheld devices. From the point at which a medication arrives at the receiving dock to the time it is administered, Omnicell systems store it, package it, bar code it, order it, issue it, and provide information and controls on its use and reorder.
Omnicell’s supply product lines provide a healthcare institution with fast, effective control of costs, capture of charges for payer reimbursement, and timely reorder of supplies. Products range from high-security closed- cabinet systems and software to open-shelf and combination solutions in the nursing unit, cath lab and operating room.
Omnicell’s mission is to provide the best customer experience in healthcare, helping hospitals reduce medication errors, operate more efficiently, and decrease costs. For more information, visit http://www.omnicell.com.
Forward-Looking Statements
To the extent any statements contained in this release deal with information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside Omnicell’s control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. The risk factors are described in Omnicell’s filings with the Securities and Exchange Commission (SEC) and include, without limitation, the continued growth and acceptance of our products and services and the continued growth of the clinical automation and workflow automation market generally, the potential of increasing competition, the ability of Omnicell to achieve profitability in the next few quarters, grow product backlog, retain key personnel, cut expenses, develop new products and integrate acquired products or intellectual property in a timely and cost-effective manner, and improve sales productivity. Prospective investors are cautioned not to place undue reliance on forward-looking statements.
Use of Non-GAAP Financial Information
This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). Our management evaluates and makes operating decisions using various performance measures. In addition to Omnicell’s GAAP results, we also consider non-GAAP gross margin, non-GAAP operating expenses, non-GAAP net income (loss), and non-GAAP earnings (loss) per share diluted. These non-GAAP results should not be considered as an alternative to gross margin, operating expenses, net income, earnings per fully diluted share, or any other performance measure derived in accordance with GAAP. We present these non-GAAP results because we consider them to be important supplemental measures of Omnicell’s performance.
Our non-GAAP gross margin, non-GAAP operating expenses, non-GAAP net income, non-GAAP earnings per fully diluted share are exclusive of certain items to facilitate management’s review of the comparability of Omnicell’s core operating results on a period to period basis because such items are not related to Omnicell’s ongoing core operating results as viewed by management. We define our “core operating results” as those revenues recorded in a particular period and the expenses incurred within that period that directly drive operating income in that period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operation performance, the measures give us a better understanding of how we should invest in research and development, fund infrastructure growth and evaluate marketing strategies. In calculating the above non-GAAP results, management specifically adjusted for the following excluded items:
Management adjusts for the excluded items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell’s control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational, or non-cash expenses involving stock option grants.
We believe that the presentation of these non-GAAP financial measures is warranted for several reasons:
Set forth below are additional reasons why specific items are excluded from our non-GAAP financial measures:
As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell’s GAAP results. In the future, we expect to incur expenses similar to the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are:
Pursuant to the requirements of SEC Regulation G, a detailed reconciliation between the company’s GAAP and non-GAAP financial results is set forth in the financial statements at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release and in the Company’s SEC filings.
CONTACT: Rob Seim, Chief Financial Officer of Omnicell, Inc.,
1-800-850-6664, ext. 6478, robs@omnicell.com
Web site: http://www.omnicell.com//